Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeting the VEGFr pathway may be effective for the treatment of AMD. Recent studies using Src/YES knockout mice suggest that along with VEGF, Src and YES play a crucial role in vascular leak and might be useful in treating edema associated with AMD. Therefore, we have developed several potent benzotriazine inhibitors designed to target VEGFr2, Src, and YES. One of the most potent compounds is 4-chloro-3-{5-methyl-3-[4-(2-pyrrolidin-1-yl-ethoxy)phenylamino]benzo[1,2,4]triazin-7-yl}phenol ( 5), a dual inhibitor of both VEGFr2 and the Src family (Src and YES) kinases. Several ester analogues of 5 were prepared as prodrugs to improve the concentration of 5 at the back of the eye after topical administration. The thermal stability of these esters was studied, and it was found that benzoyl and substituted benzoyl esters of 5 showed good thermal stability. The hydrolysis rates of these prodrugs were studied to analyze their ability to undergo conversion to 5 in vivo so that appropriate concentrations of 5 are available in the back-of-the-eye tissues. From these studies, we identified 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate ( 12), a topically administered prodrug delivered as an eye drop that is readily converted to the active compound 5 in the eye. This topically delivered compound exhibited excellent ocular pharmacokinetics and poor systemic circulation and showed good efficacy in the laser induced choroidal neovascularization model. On the basis of its superior profile, compound 12 was advanced. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD.
Palanki
Moorthy S S
MS
TargeGen Inc., 9890 Judicial Drive, San Diego, CA 92121, USA. Palanki@targegen.com
Akiyama
Hideo
H
Campochiaro
Peter
P
Cao
Jianguo
J
Chow
Chun P
CP
Dellamary
Luis
L
Doukas
John
J
Fine
Richard
R
Gritzen
Colleen
C
Hood
John D
JD
Hu
Steven
S
Kachi
Shu
S
Kang
Xinshan
X
Klebansky
Boris
B
Kousba
Ahmed
A
Lohse
Dan
D
Mak
Chi Ching
CC
Martin
Michael
M
McPherson
Andrew
A
Pathak
Ved P
VP
Renick
Joel
J
Soll
Richard
R
Umeda
Naoyasu
N
Yee
Shiyin
S
Yokoi
Katsutoshi
K
Zeng
Binqi
B
Zhu
Hong
H
Noronha
Glenn
G
D000287:Administration, Topical; D000818:Animals; D020256:Choroidal Neovascularization / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D005123:Eye / Q000187:drug effects / Q000528:radiation effects; D007834:Lasers; D008268:Macular Degeneration / Q000188:drug therapy*; D051379:Mice; D018345:Mice, Knockout; D008958:Models, Molecular; D015394:Molecular Structure; D009883:Ophthalmic Solutions / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010636:Phenols / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011355:Prodrugs / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D014227:Triazines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
C529233:4-chloro-3-(5-methyl-3-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)-1,2,4-benzotriazin-7-yl)phenol; D009883:Ophthalmic Solutions; D010636:Phenols; D011355:Prodrugs; D014227:Triazines; D040301:Vascular Endothelial Growth Factor Receptor-2; D019061:src-Family Kinases